FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

By Sneha S K March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental drug for a rare form of blood cancer ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Surgeon Gareth Honeybone wants wider access to zanidatamab to treat one of the deadliest cancers.

News, features, and commentary about cancer-related issues ...

A man who shipped counterfeit cancer drugs to Houston was sentenced to 43 months in federal prison after pleading guilty to ...

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...